Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.85 -0.55 (-1.09%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
36 37 Next >
News headline image
Will Pfizer Outgun Merck With Oral COVID-19 Pill? ↗
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,... 
Via Benzinga
News headline image
Thursday Market Overview ↗
If you are an IBM shareholder you now own something new Kyndryl. 
Via Talk Markets
News headline image
7 European Stocks to Buy to Diversify Your Portfolio ↗
While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks. 
Via InvestorPlace
News headline image
Novartis To Offload Its Stake Back To Roche For $20.7B ↗
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting... 
Via Benzinga
News headline image
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting ↗
Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in... 
Via Benzinga
News headline image
Cyber Currency ↗
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
News headline image
Default Avoided ↗
The Chinese real estate firm Evergrande managed to pay the interest it owes to foreign bondholders. 
Via Talk Markets
News headline image
Why Atea Pharmaceuticals Stock Got Crushed This Week ↗
A mid-stage trial miss caused investors to hit the exits this week. 
Via The Motley Fool
News headline image
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
News headline image
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
News headline image
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market ↗
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
News headline image
Wednesday Market Coverage ↗
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
News headline image
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics ↗
Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong... 
Via Benzinga
News headline image
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial ↗
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
News headline image
Bitcoin Futures Arrive ↗
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
News headline image
Why Atea Pharmaceuticals Is Imploding Today ↗
The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting. 
Via The Motley Fool
News headline image
Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test ↗
Atea Pharmaceuticals said its Covid pill didn't lower viral loads in all patients. 
Via Investor's Business Daily
News headline image
David v Goliath in The Race to Develop an Oral Therapy for COVID-19 ↗
Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
News headline image
Why Are Atea Pharmaceuticals Shares Plunging Today? ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate... 
Via Benzinga
News headline image
Chinese Growth Level ↗
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
News headline image
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage ↗
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
News headline image
Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops ↗
Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal. 
Via Investor's Business Daily
News headline image
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting ↗
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
News headline image
Crispr: A Fallen Angel In Gene Editing ↗
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
News headline image
Europe's Unicorns ↗
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
News headline image
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies ↗
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.